Saturday, June 13, 2009 11:37:50 AM
Sapacitabine Has Anti-Cancer Activity in Combination With Targeted Agents and Other Nucleoside Analogs
Preclinical Data Reported At European Hematology Association Congress
On Monday June 8, 2009, 10:19 am EDT
Buzz up! Print
Related: Cyclacel Pharmaceuticals, Inc.
BERKELEY HEIGHTS, N.J., June 8, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC - News; Nasdaq:CYCCP - News) announced that Cyclacel scientists reported preclinical data supporting potential combinations of sapacitabine, a novel nucleoside analog, with novel targeted agents and other nucleoside analogs for the treatment of cancer. The combinations exploit sapacitabine's unique mechanism of action and were shown to be effective in models of leukemia and solid tumors. The data were presented at a poster presentation on Saturday, June 6 at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.
Related Quotes
Symbol Price Change
CYCC 1.09 +0.18
"We are encouraged by the wide spectrum of anti-cancer agents that result in synergy when combined with sapacitabine. The EHA data extend previously reported data and support clinical evaluation of sapacitabine given with various anti-cancer agents as combination treatment for leukemia and other cancers," said Spiro Rombotis, President and CEO. "A week ago at the ASCO conference we reported interim Phase 2 data that pave the way for a pivotal trial of sapacitabine as a single agent in elderly patients with leukemia. We look forward to developing the broad therapeutic potential of sapacitabine to benefit patients in need of new treatment options."
The results, arising from a combination screen of over 30 compounds from several chemical families, showed robust synergy when sapacitabine was combined with inhibitors of cell cycle checkpoints, cell survival, and DNA repair, including targeted inhibitors of ATM, BCL2, CHK1, DNA-PK and PARP.
In addition, increased apoptosis or cancer cell death was observed when sapacitabine was administered in combination with other nucleoside analogs which inhibit ribonucleotide reductase, such as clofarabine and gemcitabine.
The findings extend previously reported data supporting the combination of sapacitabine with demethylating agents or HDAC inhibitors.
Specific targeted molecules presented in the abstract, inducing synergy when given in combination with sapacitabine, included: ABT-888 (PARP inhibitor), ABT-737 (BCL-2 inhibitor), KU55933 (ATM inhibitor), IC86621 and NU7026 (both DNA-PK inhibitors), PF-0477736 and SB218078 (both CHK1 inhibitors).
Study reference
S Frame, RH MacKay, M Hogben, C Connolly, S Anderson, IN Fleming, S Davis, D Blake, S Green, Exploiting the unique mechanism of action of sapacitabine (CYC682) to obtain synergy with other therapeutic agents for clinical use in Acute Myeloid Leukemia, 14th Congress of the European Hematology Association (EHA), June 4-7, 2009, Berlin, Germany, Abstract 0761.
The poster is available from the Cyclacel website www.cyclacel.com and the abstract is available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=102037.
About sapacitabine
Sapacitabine is an orally-available, investigational, nucleoside analog drug that acts through a dual mechanism. It interferes with DNA synthesis by causing single-strand DNA breaks and also induces arrest of cell cycle progression at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite or a substance into which the drug converts after ingestion by patients, have demonstrated potent anti-tumor activity in preclinical studies. Sapacitabine was shown to be superior in preclinical models to either gemcitabine (Gemzar®; Lilly) or ara-C, two widely used nucleoside analogs. Gemcitabine is indicated for the palliative treatment of breast, lung, pancreatic and ovarian cancer, but it has not been reported to be active in leukemias or myelodysplastic syndromes or MDS. Ara-C is indicated for the treatment of acute myeloid leukemia or AML but is typically not tolerated by elderly patients. Phase 2 trials of sapacitabine in patients with AML, MDS and non-small cell lung cancer are in progress. Sapacitabine is part of Cyclacel's deep pipeline of small molecule drugs designed to target and stop uncontrolled cell division.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
Recent CYCC News
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 01:15:00 PM
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules • GlobeNewswire Inc. • 05/02/2024 08:30:00 PM
- $8 Million Private Placement Announcement Sends Biotech Flying • AllPennyStocks.com • 04/30/2024 05:51:00 PM
- Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer • GlobeNewswire Inc. • 04/01/2024 01:15:00 PM
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/19/2024 08:05:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/07/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit • GlobeNewswire Inc. • 03/06/2024 02:15:00 PM
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 01/30/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Cyclacel Pharmaceuticals Announces Reverse Stock Split • GlobeNewswire Inc. • 12/12/2023 09:05:00 PM
- Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC • GlobeNewswire Inc. • 11/30/2023 02:15:00 PM
- Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/28/2023 10:15:00 PM
- Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/09/2023 08:05:00 PM
- Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/03/2023 01:15:00 PM
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM